BIOMAT Database Logo BIOMAT Database Logo

[Relations between insulin, somatotropic hormone and somatostatin secretions in patients with ischemic heart disease]. 1983

V N Titov, and R G Kazimov, and L V Kasatkina, and V P Masenko, and S A Beznosenko

Secretions of hormones responsible for carbohydrate metabolism, STH, insulin, S-peptide and somatostatin, were measured in coronary patients in order to investigate hormonal mechanisms involved in disordered carbohydrate metabolism. A persistent hyperinsulinemia was found in patients with disordered carbohydrate metabolism, both in cases of glucose stimulation and insulin inhibition, where glandular function was assessed on the basis of S-peptide concentration as opposed to the control level. Baseline somatostatin concentrations were beyond the method's sensitivity limit in most of the patients. There was a tendency to elevated hormonal levels in the insulin test, whereas glucose administration produced an opposite response. Blood basal STH levels did not differ significantly in the study groups, however the increase in hormonal secretion following insulin administration was less pronounced in patients with disordered carbohydrate metabolism as compared to other groups.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078790 Insulin Secretion Production and release of insulin from PANCREATIC BETA CELLS that primarily occurs in response to elevated BLOOD GLUCOSE levels. Secretion, Insulin
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone

Related Publications

V N Titov, and R G Kazimov, and L V Kasatkina, and V P Masenko, and S A Beznosenko
[Levels of cortisol, immunoreactive insulin and somatotropic hormone in the blood of patients with chronic ischemic heart disease].
November 1987, Vrachebnoe delo,
V N Titov, and R G Kazimov, and L V Kasatkina, and V P Masenko, and S A Beznosenko
[Insulin, cortisol and somatotropic hormone content of the blood in ischemic heart disease patients with varying tolerance for physical loading and varying myocardial contractile capacity].
January 1986, Terapevticheskii arkhiv,
V N Titov, and R G Kazimov, and L V Kasatkina, and V P Masenko, and S A Beznosenko
[The level of somatotropic hormone and cortisol in the blood of patients with ischemic heart disease and a rhythm disorder].
January 1997, Likars'ka sprava,
V N Titov, and R G Kazimov, and L V Kasatkina, and V P Masenko, and S A Beznosenko
[Insulin, glucagon, somatotropic hormone].
January 1972, Journees annuelles de diabetologie de l'Hotel-Dieu,
V N Titov, and R G Kazimov, and L V Kasatkina, and V P Masenko, and S A Beznosenko
Relationship between insulin sensitivity and dehydroepiandrosterone sulfate in patients with ischemic heart disease.
November 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
V N Titov, and R G Kazimov, and L V Kasatkina, and V P Masenko, and S A Beznosenko
[Somatotropic hormone deficiency and insulin discharge].
May 1971, Journees annuelles de diabetologie de l'Hotel-Dieu,
V N Titov, and R G Kazimov, and L V Kasatkina, and V P Masenko, and S A Beznosenko
Relations between endogenous androgens and estrogens in postmenopausal women with suspected ischemic heart disease.
November 2008, The Journal of clinical endocrinology and metabolism,
V N Titov, and R G Kazimov, and L V Kasatkina, and V P Masenko, and S A Beznosenko
[Behavior of immunoreactive insulin, "big insulin" and the somatotropic hormone in cirrhotic patients with diabetes mellitus].
April 1974, Folia endocrinologica,
V N Titov, and R G Kazimov, and L V Kasatkina, and V P Masenko, and S A Beznosenko
[Atherosclerotic lesion of the coronary arteries in ischemic heart disease patients with differing levels of insulin, cortisol and somatotropic hormone and the type of reactions of these hormones to physical loading].
November 1985, Kardiologiia,
V N Titov, and R G Kazimov, and L V Kasatkina, and V P Masenko, and S A Beznosenko
[Interaction of adrenocorticotropic hormone, cortisol and insulin during emotional tension among ischemic heart disease patients].
December 1985, Kardiologiia,
Copied contents to your clipboard!